CN101675041A - 用作激酶抑制剂的氨基嘧啶类化合物 - Google Patents

用作激酶抑制剂的氨基嘧啶类化合物 Download PDF

Info

Publication number
CN101675041A
CN101675041A CN200880014717A CN200880014717A CN101675041A CN 101675041 A CN101675041 A CN 101675041A CN 200880014717 A CN200880014717 A CN 200880014717A CN 200880014717 A CN200880014717 A CN 200880014717A CN 101675041 A CN101675041 A CN 101675041A
Authority
CN
China
Prior art keywords
compound
substitution
alkyl
cancer
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880014717A
Other languages
English (en)
Chinese (zh)
Inventor
H·宾奇
S·扬
C·戴维斯
M·莫蒂默尔
J·戈莱克
J·斯塔德利
D·罗宾逊
M·奥丹尼尔
D·伯雅尔
J·宾德
S·艾弗里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101675041A publication Critical patent/CN101675041A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880014717A 2007-03-20 2008-03-19 用作激酶抑制剂的氨基嘧啶类化合物 Pending CN101675041A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91901407P 2007-03-20 2007-03-20
US60/919,014 2007-03-20
US94677807P 2007-06-28 2007-06-28
US60/946,778 2007-06-28
PCT/US2008/057465 WO2008115973A2 (en) 2007-03-20 2008-03-19 Aminopyrimidines useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
CN101675041A true CN101675041A (zh) 2010-03-17

Family

ID=39743123

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880014717A Pending CN101675041A (zh) 2007-03-20 2008-03-19 用作激酶抑制剂的氨基嘧啶类化合物

Country Status (8)

Country Link
US (1) US20100137305A1 (enExample)
EP (1) EP2142537A2 (enExample)
JP (2) JP2010522194A (enExample)
CN (1) CN101675041A (enExample)
AU (1) AU2008228963A1 (enExample)
CA (1) CA2682195A1 (enExample)
MX (1) MX2009010037A (enExample)
WO (1) WO2008115973A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024246A (zh) * 2012-03-27 2014-09-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2004072029A2 (en) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US7528142B2 (en) * 2005-11-03 2009-05-05 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
ATE457311T1 (de) 2006-11-02 2010-02-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
NZ577768A (en) 2006-12-19 2012-01-12 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
AU2008226461A1 (en) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyridines useful as inhibitors of protein kinases
AU2008226466B2 (en) * 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
CN101663295B (zh) 2007-03-09 2014-11-05 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶类化合物
MX2009010037A (es) * 2007-03-20 2009-11-05 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
AU2008247594A1 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
WO2008137619A2 (en) 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
NZ582879A (en) 2007-07-31 2012-03-30 Vertex Pharma Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
US8492397B2 (en) * 2009-03-23 2013-07-23 Vertex Pharmaceuticals Incorporated Aminopyridine derivatives having Aurora A selective inhibitory action
CA2755953A1 (en) * 2009-03-24 2010-09-30 Vertex Pharmaceuticals Incorporated Novel aminopyridine derivatives having aurora a selective inhibitory action
US9382229B2 (en) * 2011-02-15 2016-07-05 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
US9023856B2 (en) 2011-11-04 2015-05-05 Cymabay Therapeutics, Inc. Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent
JPWO2013146963A1 (ja) * 2012-03-28 2015-12-14 武田薬品工業株式会社 複素環化合物
IN2014KN02601A (enExample) 2012-04-24 2015-05-08 Vertex Pharma
HK1215256A1 (zh) 2012-11-20 2016-08-19 Vertex Pharmaceuticals Incorporated 用作吲哚胺2，3-二氧化酶的抑制劑的化合物
SMT201900107T1 (it) 2013-03-12 2019-02-28 Vertex Pharma Inibitori della dna-pk
PL3424920T3 (pl) 2013-10-17 2020-11-16 Vertex Pharmaceuticals Incorporated Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
KR102523430B1 (ko) 2014-08-04 2023-04-19 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
AU2016247858B2 (en) * 2015-04-17 2020-10-15 Ludwig Institute For Cancer Research Ltd. PLK4 inhibitors
EP3490974B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
EA201990424A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые модуляторы nmda-рецептора и их применение
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
MX394860B (es) 2016-09-27 2025-03-24 Vertex Pharma Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
US11578072B2 (en) * 2018-01-31 2023-02-14 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2003002825A0 (en) * 2000-12-21 2003-09-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
AU2003220300A1 (en) * 2002-03-15 2003-09-29 Binch, Hayley Compositions useful as inhibitors of protein kinases
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
MX2009010037A (es) * 2007-03-20 2009-11-05 Vertex Pharma Aminopirimidinas utiles como inhibidores de cinasas.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104024246A (zh) * 2012-03-27 2014-09-03 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物
CN104024246B (zh) * 2012-03-27 2016-03-02 广东东阳光药业有限公司 作为欧若拉激酶抑制剂的取代嘧啶衍生物

Also Published As

Publication number Publication date
WO2008115973A3 (en) 2008-12-04
WO2008115973A2 (en) 2008-09-25
MX2009010037A (es) 2009-11-05
CA2682195A1 (en) 2008-09-25
US20100137305A1 (en) 2010-06-03
AU2008228963A1 (en) 2008-09-25
JP2010522194A (ja) 2010-07-01
EP2142537A2 (en) 2010-01-13
JP2013237703A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
CN101675041A (zh) 用作激酶抑制剂的氨基嘧啶类化合物
JP7317878B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
JP7028861B2 (ja) ピリジル置換のインドール化合物
CN107501274B (zh) 可用作atr激酶抑制剂的化合物
CN105683188B (zh) 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN107857755B (zh) 作为trka激酶抑制剂的n-吡咯烷基、n′-吡唑基-脲、硫脲、胍和氰基胍化合物
JP6424224B2 (ja) 新規ビスアミドピリジン
CN109422754A (zh) 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
CN109890819A (zh) 作为免疫调节剂的杂环化合物
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN101772500A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN101952286A (zh) 用于治疗和雄激素受体有关的病症的双环衍生物
JP2009515882A (ja) プロテインキナーゼを阻害するための方法
JP2016512239A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN101679378A (zh) 用作激酶抑制剂的噻唑和吡唑
CN101687852A (zh) 可用作激酶抑制剂的噻唑类和吡唑类化合物
CN104334557A (zh) 二酰基甘油酰基转移酶2抑制剂
JP2016512815A (ja) Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
TW201718534A (zh) ３－胺基－１，５，６，７－四氫－４ｈ－吲哚－４－酮
CN101321759A (zh) 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
JP2013082757A (ja) プロテインキナーゼ阻害薬として有用なベンズイミダゾール
TW201801729A (zh) 6-5元稠合唑環衍生物及其藥物組合物，以及作為藥物的應用
TW202227431A (zh) 可做為tlr9抑制劑之經取代雜芳基化合物
WO2022155941A1 (en) Cdk2 inhibitors
CN102482280A (zh) 作为雄激素受体的配体的[1，2，4]三唑并[4，3-b]哒嗪

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1138573

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100317

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1138573

Country of ref document: HK